PMA device
Digene Hybrid CAPTURE2
Qiagen Gaithersburg, Inc. · Kit, Dna Detection, Human Papillomavirus (MAQ, Class III) · First FDA decision Aug 12, 2009, newest Aug 12, 2009Cervical cancer and HPV
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
0
Naming "Digene Hybrid CAPTURE2"
MAUDE reports
0
Brand "Digene Hybrid CAPTURE2", since 2015
PubMed studies
0
Mentioning "Digene Hybrid CAPTURE2"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Digene Hybrid CAPTURE2
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- DIGENE HYBRID CAPTURE2PMA supplement
P890064-S020 · Decided Aug 12, 2009 · 561 days after receipt · Normal 180 Day Track No User Fee
Device type: KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS (MAQ) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Screening for Cervical Cancer with Human Papillomavirus (HPV) TestingNational analysisReview closedCAG-00442NUpdated Sep 22, 2026
- Screening for Cervical Cancer with Human Papillomavirus (HPV)National determinationOn the books210.2.1Updated Jun 17, 2020
Clinical trials
Device studies on ClinicalTrials.gov that name "Digene Hybrid CAPTURE2", any status and sponsor, newest update first.
No registered device study names "Digene Hybrid CAPTURE2".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Digene Hybrid CAPTURE2", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code MAQ
310 reports: 306 malfunction, 3 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Digene Hybrid CAPTURE2"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code MAQ.
- cobas HPVRoche Molecular Systems, Inc. · PMA 2026
- BD Onclarity HPV Assay Reagent Pack (SKU 444075) and BD COR HPV Extraction Trough (SKU 444074)Becton, Dickinson and Company · PMA 2026
- Digene Hybrid Capture 2 (HC2) Hpv Dna TestsQiagen Gaithersburg, Inc. · PMA 2015
- Alinity m HR HPVAbbott Molecular, Inc. · PMA 2026
- Cervista Hpv Hr and Genfind KitHologic, Inc. · PMA 2014
- Cervista Hpv 16/18Hologic, Inc. · PMA 2014
- Onclarity HPV AssayBecton, Dickinson and Company · PMA 2025
- Digene HC2 High Risk Hpv Dna Test and Digene HC2 Hpv Dna TestQiagen Gaithersburg, Inc. · PMA 2014
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.